ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies

American Society of Hematology. (2024).
ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies.

American Society of Hematology.
"ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies
(label-accessed April 30, 2025).

"American Society of Hematology."
ASH Letter to FDA re Secondary Malignancies Associated with CAR T Cell Therapies, 30 Apr. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-secondary-malignancies-associated-with-car-t-cell-therapies.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero